REBIRTH Therapy Study for Peripartum Cardiomyopathy

Study Purpose

The purpose of this randomized placebo controlled research study is to evaluate the impact of the investigational drug, bromocriptine, on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.

Who Can Participate

Participants 18 years and older who are newly diagnosed with peripartum cardiomyopathy post-delivery and within the first 5 months post-partum may be eligible for this study.